Q&A with Dr Ewan Hunter at Oxford Biodynamics PLC (LON:OBD)

Oxford Biodynamics PLC (LON:OBD) Director of Business Development and Head of Statistics Dr Ewan Hunter caught up with DirectorsTalk for an exclusive interview to discuss the recent published study in the Journal of Translational Medicine

 

Q1: You’ve just had a study published in the Journal of Translational Medicine, can you provide a summary of this paper?

A1: So, this is a collaboration between Oxford Biodynamics and the Scottish Early Rheumatoid Arthritis cohort in Scotland which is managed through Glasgow University. What we have done there is utilised our EpiSwitch platform to develop chromosome conformational signatures from blood in pre-treatment patients for early rheumatoid arthritis to look at the likelihood of response to the first line disease-modifying anti-rheumatic drug methotrexate.

The study successfully showed that using blood, and measuring those conformational signatures in blood, we were able to find a signature which will able to differentiate between non-responders and responders to methotrexate, with a high degree of accuracy. This was based on our proprietary EpiSwitch platform which has been developed over the course of the company.

 

Q2: What do you think the impact of this paper is in regard to precision medicine?

A2: The ability to a pre- determined clinical response to therapy in any disease indication if you wish to choose a phrase ‘the holy grail of precision medicine’ and this study using chromosome conformational signatures offers the first evidence of using this type of data modality for determining response to therapy before patients have seen therapy.

Chromosome conformational signatures offer a first-degree view of deregulation on the genome, it’s currently not capable via established molecular modalities like gene expression. This research is the first evidence that using systemic measurement of chromosome conformational signatures is capable of addressing the needs in precision medicine for patient selection and tailored therapies.

We are also doing two projects currently undergoing in Oxford Biodynamics using the same approach to determine the response to checkpoint inhibitors. When the results from this study are public, this will cement the use of the EpiSwitch platform for precision medicine.

 

Q3: How does this work fit into the landscape of chromosome architecture, the regulation of gene expression and the control of the genome via the non-coding genome?

A3: This is now a new field and what we’ve seen over the last few years is the way of evidence indicating the role of chromosome architecture, or chromosome conformations, playing the regulation of the genome.

The level of information is expanding impressively, in two recent papers, one in Nature Communications by Gaëlle Marteil and another in Nature Genetics by Di Iulio et al with Craig Venter as the senior author, have shown that the non-coding genome is responsible for the regulatory control of the genome via chromosome architecture or chromosome conformational signatures.

In the Di Iulio/Venter paper, they were looking at the constraints of the human genome based on a human variation and what they found is that the clinical relevance in their study is that the manifestation of, enrichment of, pathogenetic variants in the constrained genome is identified by chromosomes architecture which we are measuring with EpiSwitch. They have suggested that pathical implementation of their findings in the targeting of sequencing effort beyond the exome so instead of looking at a gene, they’re suggesting that many exomes could be eliminated from targeted analysis by including the equivalent amounts of sequence it represents the most non-coding region which is ultimately where chromosome architecture occurs.

 

Q4: How are Oxford Biodynamics going to extend this work?

A4: So, we’re currently have two programmes going with the extension of rheumatoid arthritis work so we’re extending the project into a couple of hundred more patients from other medical facilities in the UK, that will look at independent validation of the signature that’s been published.

We’re also working with three other medical institutions in the UK; Glasgow University, Newcastle University and Birmingham, in Glasgow we’re already looking at a project, that’s already funded, looking at rheumatoid arthritis flaring. This is where patients basically go into remission after therapy with maybe drugs like methotrexate but with time, their disease flares up and currently there’s no molecular test can look at that. The project name for that is Biological Factors that Limit Sustained Remission in Rheumatoid Arthritis or the BIO-FLARE study, this project has started and we’re currently taking patients and we’ll begin later in the year on the EpiSwitch part of the study.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that